促瘤炎症SPP1+巨噬细胞-IL6-CRP轴驱动膀胱癌免疫功能障碍
该研究整合多个ICB治疗队列、单细胞RNA测序、批量RNA测序、空间分析与功能实验,发现血浆IL6和CRP升高与肿瘤巨噬细胞浸润增加相关。免疫抑制性SPP1+巨噬细胞在高血浆IL6患者的肿瘤微环境中富集,部分通过IL6信号抑制T细胞活性,而CXCL9+巨噬细胞促进T细胞活化。这些发现将全身炎症与局部免疫功能障碍联系起来,定义了与ICB耐药相关的巨噬细胞驱动轴及可靶向的IL1β/IL6轴。
要点
- 血浆IL6和CRP升高与ICB治疗膀胱癌患者的肿瘤巨噬细胞浸润增加相关。
- SPP1+巨噬细胞部分通过IL6信号抑制T细胞活性,CXCL9+巨噬细胞促进T细胞活化。
- 血浆CRP和IL6升高标记SPP1+巨噬细胞驱动的免疫抑制,IL1β/IL6轴为可靶向的免疫治疗耐药环节。
核心结论
- 促瘤炎症SPP1+巨噬细胞-IL6-CRP轴驱动膀胱癌免疫功能障碍,与ICB耐药相关,IL1β/IL6轴为潜在治疗靶点。
研究设计与样本
- 研究整合多个ICB治疗队列的血浆IL6、CRP与肿瘤巨噬细胞浸润分析。
- 对迄今最大的尿路上皮膀胱癌图谱进行单细胞RNA测序,并结合批量RNA测序。
- 采用空间分析和功能实验验证巨噬细胞亚群对T细胞功能的影响。
主要发现
- elevated plasma IL6 and CRP associate with increased tumor macrophage infiltration across multiple ICB-treated cohorts.
- Single-cell RNA-seq integrated with bulk RNA-seq identifies enrichment of immunosuppressive SPP1+ macrophages in TMEs from patients with high plasma IL6.
- Spatial and functional analyses demonstrate that SPP1+ macrophages suppress T-cell activity partly via IL6 signaling, whereas CXCL9+ macrophages promote T-cell activation.
临床怎么用
- 血浆CRP和IL6升高可提示SPP1+巨噬细胞驱动的免疫抑制,或作为ICB疗效预测的参考指标。
- 靶向IL1β/IL6轴可能改善尿路上皮膀胱癌的免疫治疗结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Immune checkpoint blockade (ICB) has revolutionized treatment for urothelial bladder cancer, yet response rates remain limited. Inflammation promotes disease progression and treatment resistance, with macrophages shaping the tumor microenvironment (TME). Although elevated blood C-reactive protein (CRP) is associated with poor clinical outcomes in urothelial bladder cancer, its relationship to the TME remains unclear. In this study, we show that elevated plasma IL6 and CRP associate with increased tumor macrophage infiltration across multiple ICB-treated cohorts. Single-cell RNA sequencing (RNA-seq) of the largest urothelial bladder cancer atlas to date, integrated with bulk RNA-seq, identifies enrichment of immunosuppressive SPP1+ macrophages in TMEs from patients with high plasma IL6. Spatial and functional analyses demonstrate that SPP1+ macrophages suppress T-cell activity partly via IL6 signaling, whereas CXCL9+ macrophages promote T-cell activation. These findings link systemic inflammation to local immune dysfunction and define a macrophage-driven axis associated with ICB resistance and therapeutic targets to improve immunotherapy outcomes in urothelial bladder cancer. SIGNIFICANCE: Single-cell and bulk RNA-seq, spatial analyses, and functional experiments identify opposing SPP1+ and CXCL9+ macrophage programs that regulate T-cell function and ICB therapy response in bladder cancer. Elevated plasma CRP and IL6 mark SPP1+ macrophage-driven immune suppression, defining a targetable IL1β/IL6 axis that contributes to immunotherapy resistance.
引用
- Tran MA, Cho BA, Izadmehr S, et al. A Tumor-Promoting Inflammatory SPP1+ Macrophage-IL6-CRP Axis Drives Immune Dysfunction in Bladder Cancer. Cancer Discov. 2026. PMID: 41747249. doi:10.1158/2159-8290.CD-25-1774
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。